Gastro-intestinal adverse effect-free composition comprising an L-carnitine replacement
AssigneeSigma-Tau Industrie Farmaceutiche Riunite S.p.A.
InventorPaolo Carminati
Life of this patent
Estimating the term…
Abstract
Exogenous L-carnitine in the form of an equimolar amount of L-carnitine acid fumarate is administered to reduce increased volume and fluidity of stools and frequency of bowel movements relative to their usual pattern brought about by the administration of exogenous L-carnitine. Preferably nutritionally dietetically or therapeutically effective amount of L-carnitine acid fumarate is administered orally in the form of a tablet pill, capsule or powder.
Claims4
A method for reducing increased volume and fluidity of stools and frequency of bowel movements relative to their usual pattern brought about by the administration of exogenous L-carnitine to an individual in need thereof, which comprises administering to said individual an effective amount of exogenous L-carnitine in the form of an equimolar amount of L-carnitine acid fumarate.
Dependencies are inferred from the claim text.